METHODS	Patients with metastatic pancreatic cancer were randomly assigned to receive either intravenous ( i.v. ) aflibercept , 4 mg/kg every 2 weeks , or matching placebo combined with gemcitabine , 1000 mg/m ( 2 ) i.v. weekly for 7 weeks out of 8 , then weekly for 3 weeks out of 4 until progressive disease , unacceptable toxicity or withdrawal of consent .\